PE anti-human CD3 Antibody

Product Details

Verified Reactivity

Human

Antibody Type

Monoclonal

Host Species

Mouse

Formulation

Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and BSA (origin USA)

Preparation

The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.

Concentration

Lot-specific (to obtain lot-specific concentration, please enter the lot number in our Concentration and Expiration Lookup or Certificate of Analysis online tools.)

Storage & Handling

The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.

Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. For flow cytometric staining, the suggested use of this reagent is 5 µl per million cells in 100 µl staining volume or 5 µl per 100 µl of whole blood.

Excitation Laser

Blue Laser (488 nm)
Green Laser (532 nm)/Yellow-Green Laser (561 nm)

Application Notes

Additional reported (for the relevant formats) applications include: immunohistochemical staining of acetone-fixed frozen sections, immunoprecipitation, and activation of T lymphocytes^4-7. The HIT3a antibody is able to stimulate T cell activation. The LEAF™ purified antibody (Endotoxin <0.1 EU/µg, Azide-Free, 0.2 µm filtered) is recommended for functional assays (Cat. No. 300314). For highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 300332) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin <0.01 EU/µg).

Application References

1. Schlossman S, et al. Eds. 1995. Leucocyte Typing V. Oxford University Press. New York.
2. Knapp W. 1989. Leucocyte Typing IV. Oxford University Press New York.
3. Barclay N, et al. 1997. The Leucocyte Antigen Facts Book. Academic Press Inc. San Diego.
4. Sedelies KA, et al. 2004. J. Biol. Chem. 279:26581. (Activ)
5. Rivollier A, et al. 2004. Blood 104:4029. (Activ)
6. Scharschmidt E, et al. 2004. Mol. Cell Biol. 24:3860. (Activ)
7. Smeltz RB. 2007. J. Immunol. 178:4786. (Activ)
8. Enghard P, et al. 2014. Ann Rheum Dis. 73:277. PubMed

Product Citations

1. Wu Y, et al. 2021. Cancer Gene Ther. Online ahead of print. PubMed
2. Wang H, et al. 2020. J Exp Clin Cancer Res. 39:29. PubMed
3. Lin GL, et al. 2018. Acta Neuropathol Commun. 9:617. PubMed
4. Rochat MA, et al. 2018. Virol J. 15:191. PubMed
5. Bardet M, et al. 2018. Immunol Cell Biol. 96:81. PubMed
6. Galindo-Albarrán A, et al. 2016. Cell Rep. 17:2151-2160. PubMed
7. Liu F, et al. 2020. Oncoimmunology. 9:1746573. PubMed
8. Enghard P, et al. 2014. Ann Rheum Dis. 73:277. PubMed
9. Kokkinopoulos I, et al. 2021. Sci Rep. 11:15759. PubMed
10. Ma C, et al. 2021. Signal Transduct Target Ther. 6:353. PubMed
11. Wu M, et al. 2021. Nat Commun. 12:3500. PubMed
12. Wu W, et al. 2020. Oncol Lett. 0.91875. PubMed
13. Blandine Monel et al. 2019. Cell reports. 27(1):142-153 . PubMed
14. Park JA, et al. 2021. Journal for ImmunoTherapy of Cancer. 9(5):. PubMed
15. González-Jiménez A, et al. 2022. Int J Mol Sci. 23: . PubMed
16. Jackson-Jones LH, et al. 2020. Immunity. 52:700. PubMed
17. Tuganbaev T, et al. 2020. Cell. 182(6):1441-1459.e21. PubMed
18. Pellegrini JM, et al. 2021. Sci Rep. 11:13559. PubMed
19. Brown CC, et al. 2020. Cell. 179(4):846-863.e24.. PubMed
20. Woodberry T, et al. 2017. Infect Immun. 85:e00986. PubMed
21. Pereira PMR, et al. 2022. Nat Commun. 13:2526. PubMed
22. Kacherovsky N, et al. 2019. Nat Biomed Eng. 0.66875. PubMed
23. Liu J, et al. 2021. Medicine (Baltimore). 100:e24619. PubMed
24. Joly P, et al. 2017. PLoS One. 12(6):e0180568. PubMed
25. Usmani SM et al. 2019. Cell host & microbe. 25(1):73-86 . PubMed
26. Mori A, et al. 2021. Cells. :10. PubMed
27. Chulpanova DS, et al. 2021. Biology (Basel). 10:. PubMed
28. Platten M, et al. 2021. Nature. 592:463. PubMed
29. Valestrand L, et al. 2022. Am J Pathol. . PubMed
30. Park JA, et al. 2020. J Hematol Oncol. 0.661111111. PubMed
31. Cheng J, et al. 2021. Biomed Res Int. 2021:6614784. PubMed
32. Lai Y, et al. 2022. Clin Transl Med. 12:e999. PubMed
33. Wei J, et al. 2019. J Immunother Cancer. 7:209. PubMed
34. Mujib S, et al. 2017. JCI Insight. 2:e93687. PubMed
35. Łyszkiewicz M, et al. 2020. Nat Commun. 11:1031. PubMed
36. Wang X, et al. 2022. J Exp Clin Cancer Res. 41:210. PubMed
37. Hu JQ, et al. 2020. J Cancer. 3.409722222. PubMed
38. Zhai Y, et al. 2018. Autophagy. 1.714583333. PubMed
39. Pekayvaz K, et al. 2022. Nat Commun. 13:1018. PubMed
40. Ma S, et al. 2022. Nat Commun. 13:4118. PubMed

RRID

AB_314043 (BioLegend Cat. No. 300307)
AB_314044 (BioLegend Cat. No. 300308)

Antigen Details

Structure

Ig superfamily, with the subunits of CD3γ, CD3δ, CD3ζ (CD247) and TCR (α/β or γ/δ) forms CD3/TCR complex, 20 kD

Distribution

Mature T and NK-T cells, thymocyte differentiation

Function

Antigen recognition, signal transduction, T cell activation

Ligand/Receptor

Peptide antigen bound to MHC

Cell Type

T cells, NKT cells, Thymocytes, Tregs

Biology Area

Immunology

Molecular Family

CD Molecules, TCRs

Antigen References

1. Barclay N, et al. 1993. The Leucocyte FactsBook. Academic Press. San Diego.
2. Beverly P, et al. 1981. Eur. J. Immunol. 11:329.
3. Lanier L, et al. 1986. J. Immunol. 137:2501-2507.

Gene ID

916 View all products for this Gene ID

UniProt

View information about CD3 on UniProt.org

Documentation

• Technical Data Sheet (pdf)
• Certificate of Analysis
• Material Safety Data Sheet

Reviews

Related Protocols

• Cell Surface Flow Cytometry Staining Protocol

Related Pages & Pathways

Related FAQs

What type of PE do you use in your conjugates?

We use R-PE in our conjugates.

Other Formats

Concentration & Expiration Lookup

Certificate of Analysis